01:49 AM EST, 11/12/2026 (MT Newswires) -- Santhera Pharmaceuticals (SANN.SW) selected SteinCares as a distribution partner for its Duchenne muscular dystrophy treatment Agamree, or vamorolone, in Latin America and the Caribbean. The agreement covers 31 countries across the region, with an initial focus on Brazil, where SteinCares will also seek regulatory approval, the Swiss specialty pharmaceutical company said Thursday. Under the agreement, Santhera will receive a percentage of net sales, in line with its previous distribution arrangements.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.